Decreased Heart Rate Variability in COVID-19

A B S T R A C T

On March 12, 2020, the World Health Organization (WHO) announced that the coronavirus disease 2019 (COVID-19) outbreak had become a pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to Angiotensin-Converting Enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed, not only in the lungs but also in the cardiovascular system. Therefore, SARS-CoV-2 can also damage the myocardium. We analysed three COVID-19 cases that resulted in death and found that either COVID-19 or antiviral drugs could affect the coupling between the autonomic nervous system and the sinus node, thus affecting heart rate variability and preventing the heart rate from rising in response to the increase in body temperature. Early detection of the preclinical phase of cardiac autonomic dysfunction may help determine patients in need of aggressive treatment and control of cardiovascular risk factors. Antiviral drugs should be used with caution in patients with heart injury.

Keywords

The coronavirus disease 2019, angiotensin-converting enzyme 2, heart rate variability, severe acute respiratory syndrome coronavirus 2



Get access to the full version of this article.

Article Info

Article Type
Case Report and Review of the Literature
Publication history
Received: Thu 07, Oct 2021
Accepted: Sat 23, Oct 2021
Published: Mon 13, Dec 2021
Copyright
© 2021 Lei Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.JICOA.2021.04.03

Author Info

Corresponding Author
Lei Xu
Department of Critical Care Medicine, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China

Figures & Tables



Get access to the full version of this article.

References

1.     World Health Organization. Coronavirus disease (COVID-19) outbreak.

2.     http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic.

3.     Jiang F, Deng L, Zhang L, Cai Y, Cheung CW et al. (2020) Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 35: 1545-1549. [Crossref]

4.     Huang C, Wang Y, Li X, Ren L, Zhao J et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. [Crossref]

5.     Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM et al. (2020) Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study. Zhonghua Gan Zang Bing Za Zhi 28: 107-111. [Crossref]

6.     Zheng YY, Ma YT, Zhang JY, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17: 259-260. [Crossref]

7.     https://news.youth.cn/jsxw/202002/t20200205_12186073.htm.

8.     Jensen MM, Kellett JG, Hallas P, Brabrand M (2019) Fever increases heart rate and respiratory rate; a prospective observational study of acutely admitted medical patients. Acute Med 18: 141-143. [Crossref]

9.     Turner AJ, Hiscox JA, Hooper NM (2004) ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 25: 291-294. [Crossref]

10.  Wong CK, Lam CW, Wu AK, WK Ip, Lee NLS et al. (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136: 95-103. [Crossref]

11.  Chan JF, Yuan S, Kok KH, To KKW, Chu H et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395: 514-523. [Crossref]

12.  Cygankiewicz I, Zareba W (2013) Heart rate variability, Handb Clin Neurol 117: 379-393. [Crossref]

13.  Apaioannou VE, Verkerk AO, Amin AS, de Bakker JMT (2013) Intracardiac origin of heart rate variability, pacemaker funny current and their possible association with critical illness. Curr Cardiol Rev 9: 82-96. [Crossref]

14.  Seely AJE, Christou NV (2000) Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med 28: 2193-2200. [Crossref]

15.  Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC et al. (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat to beat cardiovascular control. Science 213: 220-222. [Crossref]

16.  Goldberger AL, Amaral LAN, Hausdorff JM, Ivanov PC, Peng CK et al. (2002) Fractal dynamics in physiology: alterations with disease and aging. Proc Natl Acad Sci USA 99: 2466-2472. [Crossref]

17.  Godin PJ, Buchman TG (1996) Uncoupling of biological oscillators: A complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 24: 1107-1116. [Crossref]

18.  Griffin MP, Lake DE, Bissonette EA, Harrell Jr FE, O'Shea TM et al. (2005) Heart rate characteristics: novel physiomarkers to predict neonatal infection and death. Pediatrics 116: 1070-1074. [Crossref]

19.  Zaza A, Lombardi F (2001) Autonomic indexes based on the analysis of heart rate variability: a view from the sinus node. Cardiovsc Res 50: 434-442. [Crossref]

20.  H Lu (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14: 69-71. [Crossref]

21.  Lebech AM, Kristoffersen US, Mehlsen J, Wiinberg N, Petersen CL et al. (2007) Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging 27: 363-367. [Crossref]

22.  Askgaard G, Kristoffersen US, Mehlsen J, Kronborg G, Kjaer A et al. (2011) Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: Importance of blood glucose and cholesterol. PLoS One 6: e20196. [Crossref]

23.  Dalakas MC (2001) Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6: 14-20. [Crossref]

24.  Peltier AC, Russell JW (2002) Recent advances in drug-induced neuropathies. Curr Opin Neurol 15: 633-638. [Crossref]

25.  Authier FJ, Gheradi RK (2003) Peripheral neuropathies in HIV-infected patients in the era of HAART. Brain Pathol 13: 223-228. [Crossref]

26.  Licht CM, Vreeburg SA, van Reedt Dortland AK, Giltay EJ, Hoogendijk WJG et al. (2010) Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab 95: 2458-2466. [Crossref]

27. Sakabe M, Yoshioka R, Fujiki A (2013) Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J Cardiol Cases 8: 173-175. [Crossref]